glp 1 sanofi has launched GLP-1 drug in India Sanofi nabs long-sought FDA approval

Nature 474, 307317

Location: Plainsboro, New JerseyWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Wegovy (semaglutide) injection, for subcutaneous use, Ozempic (semaglutide) injection, for subcutaneous use, and Victoza (liraglutide) injection, for subcutaneous use.FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Novo Nordisk promoted Wegovy, Ozempic, and Victoza in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner

PMID 1731620

Bei beschdigter Verpackung nicht verwenden und uns kontaktieren

FOR INFECTS OR IRRITATES THE DIGESTIVE TRACT AND IS LINKED TO BACTERIA, VIRUSES, PARASITES OR HARMFUL CHEMICALS SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases

Benefits and safety depend on the persons overall health, nutritional status, and whether a true deficiency is present